ARWR on Nasdaq
Arrowhead Pharmaceuticals
Biopharmaceutical company.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with TELIX PHARMACEUTICALS LIMITED, Harmony Biosciences Holdings, Inc. or COLLEGIUM PHARMACEUTICAL, INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
11.9%Operating margin3
-0.2%Net margin3
23258.2%Revenue growth, 20253
-0.3%Return on equity3
$156.9MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development73¢$607.2M
- Other costs24¢$200.9M
- Income tax3¢$21.4M
Out of $829.4M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending13¢$22.7M
- Kept or used elsewhere87¢$156.9M
Out of $179.6M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M |
| Research and development | $607.2M | $505.9M | $353.2M |
| General and administrative | $123.9M | $98.8M | $92.5M |
| Total operating expenses | $731.1M | $604.6M | $445.7M |
| Operating income (loss) | $98.3M | -$601.1M | -$205.0M |
| Interest income | $37.3M | $22.7M | $15.3M |
| Interest expense | -$89.4M | -$32.4M | -$18.3M |
| Other, net | $5.3M | -$1.7M | $1.5M |
| Total other expense | -$46.8M | -$11.4M | -$1.5M |
| Income (loss) before income tax expense and noncontrolling interest | $51.5M | -$612.5M | -$206.5M |
| Income tax expense (benefit) | $21.4M | -$2.8M | $2.8M |
| Net income (loss) including noncontrolling interest | $30.1M | -$609.7M | -$209.3M |
| Net income (loss) attributable to noncontrolling interest, net of tax | $31.7M | -$10.2M | -$4.0M |
| Net loss attributable to Arrowhead Pharmaceuticals, Inc. | -$1.6M | -$599.5M | -$205.3M |
| Basic (in dollars per share) | -$0.01 | -$5.00 | -$1.92 |
| Diluted (in dollars per share) | -$0.01 | -$5.00 | -$1.92 |
| Basic (in shares) | 133.8M shares | 119.8M shares | 106.8M shares |
| Diluted (in shares) | 133.8M shares | 119.8M shares | 106.8M shares |
| Unrealized gains (losses) on available-for-sale securities | $2.1M | $3.8M | -$3.0M |
| Foreign currency translation adjustments | -$432.0K | $4.2M | -$122.0K |
| Comprehensive income (loss) attributed to noncontrolling interest | $31.7M | -$10.2M | -$4.0M |
| Other comprehensive income (loss) | $31.8M | -$601.7M | -$212.4M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $226.5M | $102.7M | $110.9M |
| Accounts receivable | $6.8M | $0 | |
| Available-for-sale securities, at fair value | $692.8M | $578.3M | |
| Prepaid expenses | $10.9M | $9.5M | |
| Other current assets | $13.5M | $5.0M | |
| Total current assets | $950.6M | $695.5M | |
| Property, plant and equipment, net | $382.5M | $386.0M | |
| Intangible assets, net | $6.9M | $8.6M | |
| Right-of-use assets | $43.9M | $45.3M | |
| Other assets | $1.4M | $4.5M | |
| Total Assets | $1.4B | $1.1B | |
| Accounts payable | $17.7M | $11.4M | |
| Accrued expenses | $90.4M | $63.0M | |
| Accrued payroll and benefits | $26.9M | $22.0M | |
| Lease liabilities | $7.3M | $6.3M | |
| Deferred revenue | $2.4M | $0 | |
| Credit facility | $40.0M | $0 | |
| Other liabilities | $10.8M | $432.0K | |
| Total current liabilities | $195.5M | $103.2M | |
| Lease liabilities, net of current portion | $104.1M | $111.0M | |
| Liability related to the sale of future royalties | $367.4M | $341.4M | $268.3M |
| Credit facility, net of current portion | $214.9M | $393.2M | |
| Total long-term liabilities | $686.4M | $845.6M | |
| Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively | $231.0K | $217.0K | |
| Additional paid-in capital | $2.1B | $1.8B | |
| Accumulated other comprehensive income | $6.4M | $4.8M | |
| Accumulated deficit | -$1.6B | -$1.6B | |
| Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively | -$53.2M | $0 | |
| Total Arrowhead Pharmaceuticals, Inc. stockholders' equity | $466.1M | $185.4M | |
| Noncontrolling interest | $37.4M | $5.6M | |
| Total noncontrolling interest and stockholders' equity | $503.4M | $191.1M | $287.2M |
| Total Liabilities, Noncontrolling Interest and Stockholders' Equity | $1.4B | $1.1B | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 290.0M shares | 290.0M shares | |
| Common stock, shares issued (in shares) | 135.7M shares | 124.4M shares | |
| Common stock, shares outstanding (in shares) | 135.7M shares | 124.4M shares | |
| Treasury stock (in shares) | 2.7M shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net income (loss) | $30.1M | -$609.7M | -$209.3M |
| Stock-based compensation | $63.4M | $74.0M | $78.1M |
| Depreciation and amortization | $23.9M | $18.6M | $12.5M |
| Accretion of note premiums/discounts | -$5.8M | -$3.2M | -$2.0M |
| Non-cash interest expense on liability related to the sale of future royalties | $26.0M | $23.0M | $18.3M |
| Non-cash interest expense on credit facility | $63.3M | $9.3M | $0 |
| Non-cash gain on treasury stock received | -$3.2M | $0 | $0 |
| Realized loss on investments | $0 | $80.0K | $0 |
| Accounts receivable | -$57.0M | $0 | $1.4M |
| Prepaid expenses and other current assets | -$9.9M | -$1.7M | $11.6M |
| Accounts payable | $6.3M | -$5.5M | $33.0M |
| Accrued expenses | $41.5M | $32.1M | -$15.0M |
| Deferred revenue | $2.4M | -$866.0K | -$129.2M |
| Operating lease, net | -$4.6M | $2.2M | $46.6M |
| Other | $3.1M | -$1.2M | $0 |
| Net cash provided by (used in) operating activities | $179.6M | -$462.9M | -$153.9M |
| Purchases of property, plant and equipment | -$22.7M | -$141.5M | -$176.7M |
| Purchases of investments | -$796.3M | -$720.9M | -$246.1M |
| Proceeds from sales and maturities of investments | $689.6M | $442.3M | $326.7M |
| Net cash used in investing activities | -$129.3M | -$420.1M | -$96.2M |
| Proceeds from the exercises of stock options | $4.0M | $2.4M | $3.1M |
| Proceeds from the issuance of common stock, net of offering costs | $241.4M | $429.3M | $0 |
| Proceeds from the sale of future royalties | $0 | $50.0M | $250.0M |
| Proceeds from the issuance of warrants | $25.0M | $0 | $0 |
| Payment of debt issuance costs | -$5.0M | -$3.1M | $0 |
| Proceeds from credit facility | $0 | $392.0M | $0 |
| Repayments of credit facility | -$201.6M | $0 | $0 |
| Proceeds from Visirna credit agreement | $10.3M | $0 | $0 |
| Net cash provided by financing activities | $74.0M | $870.5M | $253.1M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $124.3M | -$12.4M | $3.0M |
| Effect of exchange rate on cash, cash equivalents and restricted cash | -$401.0K | $4.2M | -$122.0K |
| Interest paid | -$19.0K | $0 | $0 |
| Income taxes (refund) paid | $814.0K | -$3.7M | $0 |
| Treasury stock received to settle accounts receivable | $50.0M | $0 | $0 |
| Capital expenditures included in accrued expenses | $277.0K | $4.2M | $14.0M |
Former names
Timeline
- 1989Founded Founded1
Recent filings
- Aug 20, 20264
- Aug 20, 20264
- Aug 18, 2026144
- Aug 18, 2026144
- Aug 14, 2026SCHEDULE 13G/A
- Aug 4, 202610-Q
- Aug 4, 20268-K
- Jul 31, 2026SCHEDULE 13G/A
- Jun 17, 20263
- Jun 17, 20264
- Jun 16, 20268-K
- May 19, 2026144/A
- May 19, 2026144/A
- May 19, 2026144/A
- May 14, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitearrowheadpharma.com1
- WikidataQ113530745
- SEC EDGARCIK 879407
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12